title: Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma.
abstract: BACKGROUND
  Miriplatin (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC). However, rapid washout has been reported in some cases. Therefore, various methods of administration with MPT have been attempted to increase its therapeutic efficacy. One hopeful method is balloon-occluded TACE (B-TACE), but the therapeutic efficacy of B-TACE with MPT has not been evaluated.
  
  
  OBJECTIVE
  To investigate the treatment outcomes and factors involved in local recurrence after B-TACE with MPT in HCC.
  
  
  METHODS
  This study included 51 patients (55 nodules) with HCC lesions equal or less than 5 cm in diameter who underwent B-TACE with MPT between January 2012 and June 2013. Local recurrence after B-TACE with MPT and factors associated with local recurrence were evaluated.
  
  
  RESULTS
  The overall local recurrence rate was 11.1% at 6 months and 26.2% at 12 months. The local recurrence rate did differ significantly depending on CT values immediately after B-TACE with MPT. Multivariate analysis also showed that the CT value after B-TACE with MPT was the only factor related to local recurrence after B-TACE.
  
  
  CONCLUSIONS
  B-TACE with MPT achieves relatively good local control of HCC. The plain CT value immediately after B-TACE with MPT is a predictive factor for local recurrence. In patients with unsatisfactory CT values, locoregional therapy or additional treatment is required.
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Ishikawa
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Abe
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Ryousuke
authors.initials: R
authors.lastname: Inoue
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Sugano
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Yuhsuke
authors.initials: Y
authors.lastname: Watanabe
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Akito
authors.initials: A
authors.lastname: Iwanaga
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Seki
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Terasu
authors.initials: T
authors.lastname: Honma
authors.affiliation: Department of Radiology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Takeo
authors.initials: T
authors.lastname: Nemoto
authors.affiliation: Department of Radiology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Takeda
authors.affiliation: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yoshida
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D021721:Balloon Occlusion / Q000379:methods*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C406530:miriplatin